Strategic Partnership to Enhance Antibody Development
WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has announced an exciting new collaboration with Sinorda Biomedicine. This partnership aims to fast-track the development and manufacturing of SND006, an innovative bispecific antibody targeting inflammatory bowel disease (IBD) and other autoimmune conditions.
Innovative Antibody for Autoimmune Disorders
SND006 is recognized as a pioneering bispecific antibody that Sinorda Biomedicine has independently developed and holds worldwide rights to. The strategic agreement allows Sinorda to leverage WuXi Biologics' extensive manufacturing capabilities and expertise in biologics development. The two companies are poised to advance the preclinical pharmacology studies and clinical supply needed to accelerate the Investigational New Drug (IND) application process.
Commitment to Medical Advancement
Sinorda Biomedicine has successfully completed in vitro functional validation of SND006 and is preparing to submit IND applications to regulatory bodies in multiple countries. The anticipated submissions will target both the National Medical Products Administration (NMPA) in China and the U.S. Food and Drug Administration (FDA) in the upcoming year. This collaboration aims to pave the way for further projects that encompass the entire journey from molecule discovery through to clinical manufacturing.
Expert Insights from Leadership
Dr. Chris Chen, CEO of WuXi Biologics, expressed confidence in the collaboration, highlighting the company’s extensive experience with bispecific antibodies. “This partnership is expected to accelerate our ability to support Sinorda Biomedicine in developing SND006, drawing on our integrated technology platforms and comprehensive service offerings. We remain committed to transforming biologics discovery and making these advanced therapies more accessible for patients worldwide,” Dr. Chen stated.
Breaking New Ground in Treatment
In a statement from Dr. Pingsheng Hu, Chairman and General Manager of Sinorda Biomedicine, the significance of SND006 was emphasized. “This bispecific antibody has the potential to be a frontrunner in the treatment of gastrointestinal and various autoimmune disorders. Collaborating with WuXi Biologics, a recognized leader in CRDMO services, enhances our capability to address unmet medical needs and deliver safe, effective therapies,” Dr. Hu remarked. This collaboration reflects a united vision of innovation in the biopharmaceutical landscape.
About WuXi Biologics
WuXi Biologics is a prominent global CRDMO committed to providing comprehensive solutions that allow partners to successfully discover, develop, and manufacture biologics from the initial concept through to commercialization. With a dedicated team of over 12,000 employees across several countries including the United States, Ireland, Germany, and Singapore, WuXi Biologics stands ready to meet the needs of its clients.
Commitment to Sustainability
The company is not only focused on developing biologics but also prioritizes sustainability as a core aspect of its business model. WuXi Biologics invests in green technologies to create environmentally friendly CRDMO solutions while achieving excellence in Environmental, Social, and Governance (ESG) practices. This commitment ensures they foster positive impacts within the healthcare sector and the wider community.
About Sinorda Biomedicine
Founded in 2010, Sinorda Biomedicine is on the forefront of drug development, specializing in treatments for digestive tract diseases, tumor immunity, and autoimmune conditions. They have gained recognition for their innovative drug technology platform and robust clinical R&D capabilities. Sinorda has achieved significant milestones, including the commercialization of Linaprazan glureta (X842), which targets gastric acid-related disorders. Their pipeline continues to expand with promising early-stage products, including bispecific antibodies aimed at treating autoimmune diseases.
Frequently Asked Questions
What is the purpose of the collaboration between WuXi Biologics and Sinorda Biomedicine?
The collaboration is focused on developing and manufacturing SND006, a bispecific antibody aimed at treating inflammatory bowel disease and other autoimmune conditions.
What does SND006 target?
SND006 targets inflammatory bowel disease (IBD) and other autoimmune diseases, with the potential to change treatment paradigms.
Who are the key executives involved in the partnership?
Dr. Chris Chen of WuXi Biologics and Dr. Pingsheng Hu of Sinorda Biomedicine are leading this strategic collaboration.
What milestones has Sinorda Biomedicine achieved with SND006?
Sinorda Biomedicine has completed in vitro functional validation and plans to submit IND applications to regulatory authorities in China and the U.S.
How does WuXi Biologics support its clients?
WuXi Biologics provides end-to-end solutions from discovery through to clinical manufacturing, leveraging its vast experience in biologics development.
